Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

'Well-Planned, Accretive Acquisition' of Leagold Moves Equinox to Mid-Tier Status

The highlights and benefits of the transaction are provided in a Haywood report. In a Dec. 17 research note, Haywood analyst Kerry Smith purported that Equinox Gold Corp.'s (EQX:TSX.V) acquisition of Leagold Mining is "a good transaction at a good price" and recomme...
Streetwise Reports | December 27, 2019 |

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug

Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report. In a June 30 research note, H.C. Wainwright & Co. analyst Ram Selvaraju reported that the U.S. Food and Drug Administration (FDA) designated Axsome Therapeutics...
Streetwise Reports | July 2, 2020 |

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. This morning, Hamilton, Bermuda based biopharmaceutical company ...
Streetwise Reports | November 21, 2019 |

Savara Shares Double After FDA Grants Breakthrough Therapy Status for aPAP Treatment

Shares of Savara opened nearly 140% higher today after the orphan lung disease company advised that the FDA has granted Breakthrough Therapy designation for the firm's Molgradex for treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). This morning orphan lun...
Streetwise Reports | January 2, 2020 |

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results

Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. This morning Marinus Pharmaceuticals Inc. (MRNS:NASDAQ) , a pharmaceutical firm dedicated to...
Streetwise Reports | September 27, 2019 |

Analyst: Gold Explorer Warrants Top Pick Status

The rationale for this view of the company is provided in an Echelon Wealth Partners report. In an Oct. 3 research note, analyst Gabriel Gonzalez reported that Echelon Wealth Partners continues to consider Revival Gold Inc. (RVG:TSX.V) a Top Pick, as the company's 2...
Streetwise Reports | October 9, 2019 |

DNI Metals | Status on Trading, Fraud Trial, and Permits

DNI Metals (CSE: DNI | OTC: DMNKF) Dan Wei r of DNI Metals sits down with Maurice Jackson of Proven and Probable to provide shareholders updates on when trading will commence on the Canadian Stock Exchange, judicial ma...
Maurice Jackson | April 1, 2020 |

Gold Explorer Advancing Two Canadian Properties, Benefiting from New Brunswick Protection Status ...

Gold Explorer Advancing Two Canadian Properties, Benefiting from New Brunswick Protection Status of Mining Claims X-Terra Resources has the funding to simultaneously explore two of its properties. X-Terra Resources Inc.'s (XTT:TSX; XTR:FSE) gold...
Streetwise Reports | April 9, 2020 |

FDA Approval of Peanut Allergy Treatment Expected Next Year

The current status, catalysts and outlook for the immunotherapy are discussed in a ROTH Capital Partners report. In a Nov. 7 research note, ROTH Capital Partners analyst Zegbeh Jallah reported that with respect to Aimmune Therapeutics Inc. (AIMT:NASDAQ) , "all eyes r...
Streetwise Reports | November 14, 2019 |

Regenerative Medicine Firm Reports Early Results from COVID-19 Trials

Pluristem Therapeutics' coronavirus clinical studies and financing are discussed in a Dawson James report. In a June 11 research note, Dawson James analyst Jason Kolbert reported that Pluristem Therapeutics Inc. (PSTI:NASDAQ) announced the status of COVID-19-infe...
Streetwise Reports | June 18, 2020 |
1 2 3 4 5 6 7 8 9 10 ...